| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | MCTS1 |
| Uniprot No | Q9ULC4 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-181aa |
| 氨基酸序列 | MGSSHHHHHH SSGLVPRGSH MGSMFKKFDE KENVSNCIQL KTSVIKGIKN QLIEQFPGIE PWLNQIMPKK DPVKIVRCHE HIEILTVNGE LLFFRQREGP FYPTLRLLHK YPFILPHQQV DKGAIKFVLS GANIMCPGLT SPGAKLYPAA VDTIVAIMAE GKQHALCVGV MKMSAEDIEK VNKGIGIENI HYLNDGLWHM KTYK |
| 预测分子量 | 23 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于MCTS1重组蛋白的模拟参考文献示例(注：内容为虚构，仅供格式参考)：
1. **文献名称**：*MCTS1重组蛋白通过调控c-Myc促进肿瘤细胞增殖的机制研究*
**作者**：Zhang L, et al.
**摘要**：本研究通过体外表达MCTS1重组蛋白，发现其与c-Myc蛋白直接结合，增强c-Myc稳定性，进而激活下游细胞周期相关基因，促进肿瘤细胞增殖。
2. **文献名称**：*MCTS1重组蛋白的结构解析及其在白血病中的功能*
**作者**：Smith JR, et al.
**摘要**：利用X射线晶体学解析MCTS1重组蛋白的三维结构，揭示其KH结构域在RNA结合中的关键作用，并通过敲低实验证明MCTS1在急性T细胞白血病中的促存活功能。
3. **文献名称**：*重组MCTS1蛋白作为癌症免疫治疗潜在靶点的探索*
**作者**：Wang Y, et al.
**摘要**：研究发现MCTS1在多种实体瘤中高表达，重组蛋白可诱导特异性T细胞反应，动物实验显示靶向MCTS1的疫苗能显著抑制肿瘤生长。
4. **文献名称**：*MCTS1重组蛋白通过PI3K/AKT通路调控自噬的分子机制*
**作者**：Kim H, et al.
**摘要**：通过体外重组蛋白递送实验，证明MCTS1通过激活PI3K/AKT通路抑制自噬，增强化疗耐药性，为联合靶向治疗提供依据。
(注：以上内容为模拟生成，实际文献需通过PubMed/Google Scholar等平台检索确认。)
MCTS1 (Malignant T-cell-amplified sequence 1), also known as MCTS1 re-initiation and release factor, is a protein-coding gene implicated in cellular proliferation, apoptosis regulation, and oncogenesis. The recombinant MCTS1 protein, produced through genetic engineering techniques, retains the functional domains of the native protein and serves as a critical tool for studying its biological roles and therapeutic potential. Structurally, MCTS1 contains a conserved PRRC2C domain and interacts with key translation initiation factors like eIF4E, enabling its involvement in mRNA translation re-initiation—a process vital for synthesizing oncoproteins and stress-response proteins.
Research highlights MCTS1's overexpression in multiple cancers, including hepatocellular carcinoma, glioblastoma, and breast cancer, where it promotes tumor progression by enhancing cell cycle transition, inhibiting apoptosis, and activating oncogenic pathways like Wnt/β-catenin and PI3K/AKT. Its recombinant form facilitates mechanistic studies in vitro, allowing precise analysis of protein-protein interactions and downstream signaling. Additionally, MCTS1 recombinant protein has been utilized to develop monoclonal antibodies for diagnostic applications and to explore its role in non-cancer contexts, such as neurodevelopment and immune modulation.
Recent studies also investigate MCTS1's potential as a therapeutic target, with recombinant protein-based assays aiding in drug screening for small-molecule inhibitors. Despite progress, challenges remain in fully elucidating its tissue-specific functions and regulatory networks. The development of MCTS1 recombinant proteins continues to advance both basic research and translational applications in oncology and molecular biology.
×
